475 Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockadeNamrata S. Patil, David S. Shames, Raymond D. Meng et al.|Regular and Young Investigator Award Abstracts|2022Cited by 3
Supplementary Figure 2 from Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Alexander I. Spira, Anthony B. El-Khoueiry et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Alexander I. Spira, Navid Hafez et al.|Unknown|2023Cited by 0
Supplementary Data is word format from Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Alexander I. Spira, Anthony B. El-Khoueiry et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Alexander I. Spira, Anthony B. El-Khoueiry et al.|Unknown|2023Cited by 0